Finding innovative, minimally invasive ways to treat liver cancerand being able to tailor that treatment individually to patientsare hallmarks of interventional radiologists. Advances in yttrium-90 (Y-90) radioembolization for liver cancer, a leading cause of cancer deaths worldwide, are reported in studies in the October Journal of Vascular and Interventional Radiology.
"Results of these two new studies may be beneficial to patients with liver tumors that cannot be surgically removed," said Daniel Sze, M.D., Ph.D., FSIR, professor of interventional radiology at Stanford University Medical Center, Stanford, Calif. "These studies address methods to modify the blood vessels of the liver in order to maximize delivery of tumor-killing material to the targets and to make treatment simpler and safer," he added.
"Blood supply to tumors can be complex and can present challenges for interventional radiologists," said Riad Salem, M.D., MBA, FSIR, who wrote an accompanying commentary in JVIR. "This research advances the field and provides information that is immediately applicable to all interventional radiologists when treating their cancer patients," said Salem, professor of radiology, medicine and surgery and director of interventional oncology, division of interventional radiology, in the department of radiology at Northwestern University in Chicago, Ill. "Such research allows interventional radiologists to tailor treatments to help even the sickest patients achieve a better quality of life," he explained.
Worldwide, primary liver cancer accounts for an estimated 600,000 deaths annually. Last year, it was estimated that 24,120 new cases of primary liver cancer and intrahepatic (within the liver) bile duct cancer would be diagnosed and 18,910 people would die of these cancers in the United States. Primary liver cancer shows the most rapidly increasing incidence of all cancers in this country. In addition, roughly ten times as many p
|Contact: Ellen Acconcia|
Society of Interventional Radiology